RxDoctor Payments Data

Danielle Anderson, MD

Psychiatry · Milwaukee, WINPI 1063568202

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 54 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$525
  • Biohaven Pharmaceuticals, Inc.$127
  • Eisai Inc.$100
  • Catalyst Pharmaceuticals, Inc.$90
  • AstraZeneca$33
  • Teva Pharmaceuticals USA, Inc.$27
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$1,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,044 in reported general payments places this provider in the 80th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$192,225
Medicare patients
232
Services billed
1,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant12$7,049
TrintellixVortioxetine Hydrobromide11$5,059
VyvanseLisdexamfetamine Dimesylate11$4,249
Bupropion XlBupropion Hcl124$2,290
Quetiapine Fumarate95$2,258
Trazodone Hcl151$2,154
Venlafaxine Hcl ErVenlafaxine Hcl109$2,121
Mirtazapine123$2,080
Duloxetine Hcl114$1,891
Clozapine14$1,436
Gabapentin123$1,419
Paliperidone ErPaliperidone11$1,360
Clonazepam63$1,325
Aripiprazole31$1,168
Lamotrigine100$1,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$26$98059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →